Pharmaceuticals News and Research

RSS

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

RXi Pharmaceuticals Corporation, a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, today announced that results from a blinded panel and an Investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Aratana announces $40 million senior secured credit facility

Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced a $40 million senior secured credit facility with Pacific Western Bank, as agent and lender, and Oxford Finance LLC, as lender. The facility refinances the $15 million loan facility previously provided to the Company by Pacific Western Bank (as successor-in-interest to Square 1 Bank).

16 Oct 2015

WSU scientist wins federal grant to explore metabolism pathways, tobacco carcinogens

A Washington State University researcher has received a $2.6 million federal grant to study the body's ability to keep tobacco smoke components from causing cancer.

16 Oct 2015

Researchers create high resolution images of telomerase that plays major role in cancer, aging

An enzyme called telomerase plays a significant role in aging and most cancers, but until recently many aspects of the enzyme's structure could not be clearly seen.

16 Oct 2015

Rutgers-led research consortium receives NIH grant to support continuous manufacturing systems for pharmaceuticals

The U.S. Food and Drug Administration (FDA) has awarded $4.9 million in grant funding to institutions in a research consortium based at the Rutgers University School of Engineering to support the introduction of continuous manufacturing techniques for pharmaceuticals.

16 Oct 2015

US and German researchers team up to advance quality control of human stem cells

Researchers at The Scripps Research Institute (TSRI) in California, USA, and two German institutes, the Center for Integrated Psychiatry Kiel (ZIP) and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, have announced a partnership to advance the quality control of human stem cells.

16 Oct 2015

Lack of patient understanding of the true cost of medication non-adherence

A new report released today, Friday 16th October, by Omnicell, throws the spotlight on the ‘missing millions’ in the NHS and the staggering cost to the nation of medication non-adherence.

16 Oct 2015

New manganese-based catalyst may accelerate drug discovery, development

Chemists have long believed that inserting nitrogen -- a beneficial ingredient for making many pharmaceuticals and other biologically active molecules -- into a carbon-hydrogen bond requires a trade-off between catalyst reactivity and selectivity.

15 Oct 2015

Merck unveils new global brand as a science and technology company

Merck, a leading science and technology company, today announced the relaunch of its brand identity. The fundamental revision of the visual appearance as well as the introduction of a new logo reflect the transformation into a global science and technology company. At the same time, the brand architecture at business level has been simplified. Outside the United States and Canada, the company will operate uniformly as Merck.

15 Oct 2015

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize new therapies for inflammatory bowel disease (IBD).

14 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Researchers from Isis Pharmaceuticals (Carlsbad, CA) and Prysis Biotechnologies (Pudong, Shanghai, China) have demonstrated proof-of-concept for using a sense oligonucleotide to undo the effects of an antisense drug, an antithrombotic agent in this novel study.

14 Oct 2015

Malaria protein could one day help stop cancer

Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.

13 Oct 2015

XTL signs agreement with Yeda to amend development milestones for lupus treatment

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of unmet clinical needs with a focus on treatments for autoimmune diseases, today announced that it has reached agreement with Yeda Research and Development Company Ltd. to amend the development milestones in the License Agreement signed between the parties in January 2014 for the development of hCDR1 for the treatment of systemic lupus erythematosus (SLE).

13 Oct 2015

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Novartis announced today new late-breaking data demonstrating that CosentyxTM provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.

13 Oct 2015

Tamoxifen drug clears MRSA, reduces mortality

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling them to respond to, ensnare and kill bacteria in laboratory experiments. Tamoxifen treatment in mice also enhances clearance of the antibiotic-resistant bacterial pathogen MRSA and reduces mortality.

13 Oct 2015

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

The Pharmacy Compounding Accreditation Board (PCAB) today reaffirmed the accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA.

13 Oct 2015

Study explains why anemia is a common side effect of anti-cancer drugs

Many types of leukemia are caused by loss of enzymes such as Pten, which normally keeps cell growth in check, or conversely, the over-activation of enzymes that normally enhance cell proliferation, such as Shp2.

13 Oct 2015

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

Astute Medical, Inc. today announced the signing of an agreement with Shanghai Fosun Long March Medicine Science Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., for distribution of Astute's NephroCheck Test on the Astute140 Meter in China. In addition to its planned launch of the NephroCheck Test in China, FOSUNPHARMA invested $20 million in Astute.

12 Oct 2015

Pharmaceuticals News and Research

RXI-109 use after scar revision surgery has beneficial effect on suppression of hypertrophic scarring

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Aratana announces $40 million senior secured credit facility

WSU scientist wins federal grant to explore metabolism pathways, tobacco carcinogens

Researchers create high resolution images of telomerase that plays major role in cancer, aging

Rutgers-led research consortium receives NIH grant to support continuous manufacturing systems for pharmaceuticals

US and German researchers team up to advance quality control of human stem cells

Lack of patient understanding of the true cost of medication non-adherence

New manganese-based catalyst may accelerate drug discovery, development

Merck unveils new global brand as a science and technology company

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Malaria protein could one day help stop cancer

XTL signs agreement with Yeda to amend development milestones for lupus treatment

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Tamoxifen drug clears MRSA, reduces mortality

PCAB reaffirms accreditation of Harbor Compounding Pharmacy in Costa Mesa, CA

Study explains why anemia is a common side effect of anti-cancer drugs

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

A guide to density measurement excellence eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring